Camp4 Therapeutics vs Rani Therapeutics
CAMP and RANI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CAMP and RANI compare
Camp4 Therapeutics is the larger company, worth 3.3 times as much as Rani Therapeutics ($238M against $73.4M).
Rani Therapeutics grew revenue faster over the last twelve months (449% versus 39.9% for Camp4 Therapeutics).
Rani Therapeutics keeps more of each dollar of sales as profit, with a net margin of −493% compared with −2276% at Camp4 Therapeutics.
Camp4 Therapeutics scores higher on the StockData Score (6 against 2 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CAMP | RANI |
|---|---|---|
| Size and price | ||
| Market cap | $238M | $73.4M |
| Share price | $3.80 | $0.526 |
| Change, 1 year | −13.4% | −75.2% |
| Change, 5 years | −98.3% | −98.5% |
| Beta (5Y) | 2.72 | 0.85 |
| Employees | 48 | 69 |
| StockData Score | ||
| Total score | 6 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 44.8× | 11.1× (better) |
| P/B | 2.2× | 2.2× (better) |
| FCF yield | −11.1% (better) | −31.7% |
| Fair value | $2.42 | $0.366 |
| Margin of safety | −57.2% | −43.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 39.9% | 449% (better) |
| Revenue growth, 5Y average | – | 28.7% |
| Profitability | ||
| Operating margin | −1001% | −530% (better) |
| Net margin | −2276% | −493% (better) |
| FCF margin | −496% | −353% (better) |
| Return on equity | −146% (better) | −249% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −71.9× |
| Current ratio | 6.42 (better) | 5.26 |
| Altman Z-score | 1.11 (better) | −1.36 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 66.5% | 32.7% |
| Held by insiders | 21.7% | 30.6% |
| Insider net buying, 12 months | −$2.4M | $49.7K (better) |
| Short interest, % of float | 6.6% | 8.5% |
Go deeper
- CAMP stock overview
- CAMP income statement
- CAMP valuation and score
- RANI stock overview
- RANI income statement
- RANI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.